Trial Profile

Effects of Different Dosing and Feeding Intervals on the Pharmacokinetic Parameters of Herombopag Olamine Tablets

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hetrombopag (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Adverse reactions
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

18 Feb 2020 Results assessing effect of Post-dose Fasting Duration on Hetrombopag Olamine Pharmacokinetics and Pharmacodynamics in Healthy Volunteers published in the British Journal of Clinical Pharmacology
05 May 2019 Status changed from recruiting to completed.
01 Aug 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com